IL2RA and breast cancer: All the relevant studies have indicated that the elimination or silencing of Tregs could be a desirable therapeutic objective for BC and that surface molecules expressed by Tregs can be specifically targeted by (daclizumab: anti-CD25 Ab) Abs or pharmacological inhibitors.